REGENXBIO Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $170.4M | $83.3M | $90.2M | $112.7M | $470.3M |
| Cost of revenue | — | $33.6M | $37.2M | $54.5M | $51.8M |
| Research and development | $228.3M | $208.5M | $232.3M | $242.5M | $181.4M |
| Operating income | -$161.2M | -$233.3M | -$268.1M | -$262.9M | $160.0M |
| Interest expense | $45.0M | $12.7M | $6.9M | $23.3M | $26.3M |
| Pretax income | -$193.9M | -$227.1M | -$263.6M | -$280.4M | $141.2M |
| Income tax expense | $0 | $0 | -$152,000 | -$84,000 | $13.4M |
| Net income | -$193.9M | -$227.1M | -$263.5M | -$280.3M | $127.8M |
| Balance Sheet | |||||
| Cash and equivalents | $34.5M | $57.5M | $34.5M | $97.0M | $345.2M |
| Current assets | $281.3M | $278.0M | $335.0M | $416.0M | $518.8M |
| Total assets | $453.0M | $466.0M | $574.0M | $833.3M | $1.1B |
| Current liabilities | $118.1M | $103.2M | $130.3M | $130.4M | $130.5M |
| Total liabilities | $350.3M | $206.3M | $262.2M | $317.1M | $349.6M |
| Stockholders' equity | $102.7M | $259.7M | $311.7M | $516.2M | $764.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$124.0M | -$173.1M | -$218.4M | -$207.5M | $218.9M |
| Depreciation and amortization | $15.6M | $16.2M | $17.3M | $12.9M | $9.6M |
| Stock-based compensation | $34.6M | $38.5M | $40.3M | $40.8M | $38.8M |
| Capital expenditure | $2.4M | $2.4M | $10.0M | $30.7M | $84.2M |
| Free cash flow | -$126.4M | -$175.6M | -$228.4M | -$238.2M | $134.7M |
| Impairments | — | $2.1M | $0 | $0 | $0 |
Shares outstanding 51.7M · Free float 72.4%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.